VitaDAO
3456 Paul Anka Drive, Ottawa, Ontario, K1V 9K6, Canada
Overview
VitaDAO is a decentralized collective funding early stage longevity research Our mission is to extend human lifespan by researching, financing, and commercializing longevity therapeutics in an open and democratic manner. VitaDAO and its members are committed to nurturing and developing the intellectual property, licenses, and data sets that result from the projects it supports. Members can join VitaDAO by purchasing VITA tokens or earning them through contributions of work or Intellectual Property.
- Total investments
- 2
- Lead investments
- 1
- Investments · 12mo
- 1
- Active investors
- 5
Sector focus
- Biotechnology
- Blockchain
- Life Science
- Pharmaceutical
Investment portfolio
- ARTAN Bio
Led · Seed · Jun 2026
ARTAN Bio is developing a proprietary engineered suppressor tRNA platform (ARTAN-102) designed to selectively recognize disease-causing nonsense codons and restore normal protein translation. The company has completed initial in-cell validation of ARTAN-102 and is positioning the program for in vivo validation and advancement toward a preclinical development candidate. ARTAN Bio raised a $200,000 seed round through a decentralized funding model with VitaDAO, using VITARNA tokens and an IP-NFT issuance on the Molecule AG platform to align community governance with research decisions. Planned use of funds includes animal model validation, preclinical candidate advancement, and intellectual property filings to protect the platform. ARTAN Bio describes its approach as mutation-specific and claims applicability across multiple aging-associated conditions. The company is headquartered in St. Petersburg, Florida and operates within an open, community-driven DeSci framework.
- ImmuneAGE Bio
Participated · Seed · Jul 2024
ImmuneAGE Bio has built a drug-discovery platform that targets hematopoietic stem cells (HSCs) in the bone marrow to rejuvenate the entire immune system. The platform enables large-scale ex vivo combinatorial drug screening for geroprotective cocktails and reportedly achieves 1,000x expansion of HSCs, a >70x improvement over prior efforts. The company is advancing three programs: IA-101 (an oral small-molecule immune booster for respiratory infections and vaccine response in elderly patients), IA-201 (an ex vivo immune-rejuvenation cocktail for peripheral mobilized HSCs targeting chemotherapy recovery and bone marrow transplantation), and IA-301 (an HSC expansion platform for bone marrow transplantation and other immune cell types such as T cells). ImmuneAGE has raised $2M to date and is now raising a seed round to further advance these programs. The company operates from San Juan, Puerto Rico and Lausanne, Switzerland and collaborates with teams at the University of Oxford and University of Lausanne.